Sugi Predict

Sugi Predict / Compounds / SCHEMBL130220

SCHEMBL130220

SCHEMBL130220

C=CCCCCCCCN

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.52
▸ DNM1 Q05193 4/20 0.50
▸ CA12 O43570 2/20 0.50
▸ CA1 P00915 2/20 0.50
▸ CA2 P00918 2/20 0.50
▸ CA3 P07451 2/20 0.50
▸ CA4 P22748 2/20 0.50
▸ CA6 P23280 2/20 0.50
▸ CA5A P35218 2/20 0.50
▸ CA7 P43166 2/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ CA14 Q9ULX7 2/20 0.50
▸ CA5B Q9Y2D0 2/20 0.50
▸ LMNA P02545 1/20 0.50
▸ BLM P54132 1/20 0.50
▸ ABCC4 O15439 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ TRPA1 O75762 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL131171 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2
SCHEMBL2140212 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2
SCHEMBL133481 1.00 — —
SCHEMBL19774576 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2
SCHEMBL132137 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2
SCHEMBL129565 1.00 — —
SCHEMBL8954646 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2
SCHEMBL3168896 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2
SCHEMBL131017 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2
SCHEMBL130546 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122012037-A Organosilicon cooling liquid and preparation method thereof 山东诺唯亚新材料有限公司 2026-05-12 — — CN disclosed
US-12570676-B2 Multifunctionalized silicon nanoparticles, process for their preparation and uses thereof in electrochemiluminescence based detection methods ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2026-03-10 — — US disclosed
US-20260035391-A1 SILANE COMPOUND DAIKIN INDUSTRIES, LTD. (JP) 2026-02-05 — — US disclosed
EP-4678645-A1 SILANE COMPOUND Daikin Industries, Ltd. (JP) 2026-01-14 — — EP disclosed
US-20250361250-A1 FLUORINE-CONTAINING SILANE COMPOUND DAIKIN INDUSTRIES, LTD. (JP) 2025-11-27 — — US disclosed
WO-2025028568-A1 SURFACE TREATMENT AGENT ダイキン工業株式会社 2025-02-06 — — WO disclosed
WO-2024214748-A1 SILANE COMPOUND ダイキン工業株式会社 2024-10-17 — — WO disclosed
WO-2024172034-A1 FLUORINE-CONTAINING SILANE COMPOUND ダイキン工業株式会社 2024-08-22 — — WO disclosed
EP-3504155-B1 MULTIFUNCTIONALIZED SILICON NANOPARTICLES AND USES THEREOF IN ELECTROCHEMILUMINESCENCE BASED DETECTION METHODS ROCHE DIAGNOSTICS GMBH (DE) 2023-03-08 — — EP disclosed
CN-115010751-A Phosphorus-nitrogen type multifunctional additive and preparation method thereof 新乡市瑞丰新材料股份有限公司 2022-09-06 — — CN disclosed
EP-1510207-A1 THERAPEUTIC DRUG FOR DIABETES Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 — — EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 — — US disclosed
CN-1498205-A Aryl and biaryl compounds having MCH modulatory activity �����Ƥ�� 2004-05-19 — — CN disclosed
EP-1370520-A1 ARYL AND BIARYL COMPOUNDS HAVING MCH MODULATORY ACTIVITY PHARMACOPEIA, INC. (US) 2003-12-17 — — EP disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 — — EP disclosed
US-20030092715-A1 Aryl and biaryl compounds having MCH modulatory activity SCHERING CORPORATION 2003-05-15 — — US disclosed
WO-2002076929-A1 ARYL AND BIARYL COMPOUNDS HAVING MCH MODULATORY ACTIVITY PHARMACOPEIA, INC. (US) 2002-10-03 — — WO disclosed
EP-0421441-B1 Pantothenic acid derivatives FUJIREBIO KK (JP) 1995-01-25 — — EP disclosed
US-5120738-A Cardiovascular disorders FUJIREBIO INC. (JP) 1992-06-09 — — US disclosed
EP-0421441-A2 Pantothenic acid derivatives FUJIREBIO INC. (JP) 1991-04-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570676-B2 Multifunctionalized silicon nanoparticles, process for their preparation and uses thereof in electrochemiluminescence based detection methods SELP, SELPLG, SELE TSHR 2033/4885DNM1 4558/4885CA12 52/4885
US-20260035391-A1 SILANE COMPOUND OXER1, CBR1, MSR1 TSHR 1167/4885DNM1 1157/4885CA12 544/4885
US-20250361250-A1 FLUORINE-CONTAINING SILANE COMPOUND FLI1, AFF1, RFT1 TSHR 2035/4885DNM1 807/4885CA12 831/4885
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB TSHR 4035/4885DNM1 4569/4885CA12 4370/4885
US-20030092715-A1 Aryl and biaryl compounds having MCH modulatory activity MCHR1, MCHR2, MC3R TSHR 128/4885DNM1 2242/4885CA12 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.